^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Thyroid Gland Hurthle Cell Carcinoma
    Drug:Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Scottish Medicines Consortium
    Title:

    lenvatinib (Lenvima) is accepted for use within NHS Scotland.

    Published date:
    09/09/2016
    Excerpt:
    lenvatinib (Lenvima) is accepted for use within NHS Scotland...treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    05/28/2015
    Excerpt:
    Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Hurthle cell cancer: Consider systemic therapy…For progressive and/or symptomatic disease, consider lenvatinib (preferred) or sorafenib...